Clinical Trials Browser

Completed × Interventional × Everolimus × Clear all

NCT02520063 2026-02-06

Combination of Letrozole, Everolimus and TRC105 in Postmenopausal Women With Hormone-Receptor Positive and Her2 Negative Breast Cancer

Phase 1/2 Completed

15 enrolled 18 charts

Breast Neoplasms

NCT00799188 2025-12-19

CERTICOEUR

Phase 3 Completed

Skin Neoplasms

NCT01582191 2025-10-27

Vandetanib and Everolimus in Treating Patients With Advanced or Metastatic Cancer

Phase 1 Completed

Neoplasm Metastasis, Neoplasms, Recurrence

NCT05501769 2025-09-26

TACTIVE-E

Phase 1 Completed

Breast Neoplasms

NCT01120249 2025-09-16

S0931

Phase 3 Completed

1,545 enrolled 15 charts

Carcinoma, Renal Cell, Kidney Neoplasms

NCT02123823 2025-07-15

BI 836845 in Estrogen Receptor Positive Metastatic Breast Cancer

Phase 1 Completed

164 enrolled 21 charts

Neoplasms

NCT03834740 2025-05-30

A Phase 0/I Study of Ribociclib (LEE011) in Combination With Everolimus in Preoperative Recurrent High-Grade Glioma Patients Scheduled for Resection

Phase EARLY_PHASE1 Completed

27 enrolled 17 charts

Brain Neoplasms, Glioblastoma, Glioma

NCT02246127 2025-05-11

SEQTOR

Phase 3 Completed

141 enrolled 27 charts

Neuroendocrine Tumors

NCT00113360 2025-05-01

RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma

Phase 2 Completed

67 enrolled 6 charts

Carcinoma, Islet Cell, Carcinoma, Neuroendocrine

NCT00449748 2025-05-01

Everolimus (RAD001) as Therapy for Patients With Systemic Mastocytosis

Phase 2 Completed

10 enrolled 4 charts

Mastocytosis, Systemic

NCT00942734 2025-05-01

Trial of RAD001 and Erlotinib With Recurrent Head and Neck Squamous Cell Carcinoma

Phase 2 Completed

49 enrolled 5 charts

Carcinoma, Squamous Cell, Head and Neck Neoplasms

NCT00081874 2025-04-27

RAD001 in Relapsed or Refractory AML, ALL, CML in Blastic-Phase, Agnogenic Myeloid Metaplasia, CLL, T-Cell Leukemia, or Mantle Cell Lymphoma

Phase 1/2 Completed

LymphoidMyeloidOther hematologic neoplasm

Leukemia, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, T-Cell, Leukemia, Myeloid, Acute, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Primary Myelofibrosis

NCT03324373 2025-04-24

Lenvatinib and Everolimus in Renal Cell Carcinoma (RCC)

Phase 1 Completed

Carcinoma, Renal Cell

NCT04339062 2025-04-23

CONTRAC

Phase 1/2 Completed

12 enrolled 13 charts

Cutaneous Squamous Cell Carcinoma

NCT03173560 2025-04-01

Trial to Assess Safety and Efficacy of Lenvatinib (18 mg vs. 14 mg) in Combination With Everolimus in Participants With Renal Cell Carcinoma

Phase 2 Completed

343 enrolled 25 charts

Carcinoma, Renal Cell

NCT02531932 2025-02-19

Comparison of Single-Agent Carboplatin vs the Combination of Carboplatin and Everolimus for the Treatment of Advanced Triple-Negative Breast Cancer

Phase 2 Completed

Breast Neoplasms

NCT02842749 2025-02-10

Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China

Phase 4 Completed

61 enrolled 9 charts

EndocrineGastrointestinalNET

Pancreatic Neuroendocrine Tumors

NCT02216786 2024-12-02

MANTA

Phase 2 Completed

Estrogen Receptor Positive Breast Cancer

NCT03070301 2024-10-10

A Study of LEE011 With Everolimus in Patients With Advanced Neuroendocrine Tumors

Phase 2 Completed

21 enrolled 8 charts

Neuroendocrine Tumors

NCT01678664 2024-09-25

EVACEL

Phase 2 Completed

74 enrolled 10 charts

Neoplasm Metastasis, Neoplasms, Neuroendocrine Tumors

NCT00655655 2024-08-21

Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors

Phase 1 Completed

DermatologicEndocrineGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Glucagonoma, Insulinoma, Melanoma, Pheochromocytoma, Somatostatinoma, Carcinoma, Merkel Cell, Gastrinoma, Carcinoma, Islet Cell, Carcinoma, Medullary

NCT03154281 2024-08-01

Evaluation of the Safety and Tolerability of Niraparib With Everolimus in Advanced Gynecologic Malignancies and Breast

Phase 1 Completed

14 enrolled 12 charts

BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms

NCT01523977 2024-07-18

CRAD001NUS175T

Phase 1 Completed

LymphoidOther hematologic neoplasm

Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02155920 2024-05-08

Everolimus for Children With Recurrent or Progressive Ependymoma

Phase 2 Completed

11 enrolled 13 charts

Familial ependymoma, Ependymoma

NCT02456857 2024-02-13

Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot Initiative

Phase 2 Completed

17 enrolled 8 charts

Triple Negative Breast Neoplasms

NCT03312738 2024-01-23

BOLERO-5

Phase 2 Completed

159 enrolled 25 charts

Breast Neoplasms

NCT02332902 2023-12-20

DCLNF1

Phase 2 Completed

24 enrolled 4 charts

Neurofibroma, Neurofibromatosis 1

NCT02258451 2023-11-24

Study of Radium-223 Dichloride in Combination With Exemestane and Everolimus Versus Placebo in Combination With Exemestane and Everolimus in Subjects With Bone Predominant HER2 Negative Hormone Receptor Positive Metastatic Breast Cancer

Phase 2 Completed

283 enrolled 22 charts

Breast Neoplasms

NCT02599324 2023-11-18

Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors

Phase 1/2 Completed

263 enrolled 34 charts

Carcinoma, Renal Cell

NCT01827384 2023-09-29

MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene Variations

Phase 2 Completed

208 enrolled 27 charts

Other solid neoplasm

Advanced Malignant Solid Neoplasm

NCT01298713 2023-09-06

Tamoxifen-RAD001 Versus Tamoxifen Alone in Patients With Anti-aromatase Resistant Breast Metastatic Cancer

Phase 2 Completed

Breast Neoplasms

NCT03245151 2023-08-30

Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors

Phase 1/2 Completed

64 enrolled 29 charts

Glioma, Recurrence, Rhabdomyosarcoma, Central Nervous System Neoplasms, Neuroectodermal Tumors, Primitive, Peripheral

NCT02028364 2023-08-24

PEARL

Phase 2 Completed

Breast Neoplasms

NCT00255788 2023-08-04

Everolimus in Treating Patients WIth Recurrent or Metastatic Breast Cancer

Phase 2 Completed

Breast Neoplasms, Breast Neoplasms, Male

NCT00387400 2023-08-04

Temozolomide + Everolimus in Newly Diagnosed, Recurrent, or Progressive Malignant Glioblastoma Multiforme

Phase 1 Completed

Brain Neoplasms, Glioblastoma, Central Nervous System Neoplasms, Gliosarcoma

NCT03328104 2023-07-21

ENCERT

Phase 1 Completed

LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT01430572 2023-06-06

Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss Patients

Phase 1 Completed

Other solid neoplasm

Advanced Cancers

NCT02106507 2023-05-26

ARN 509 Plus Everolimus in Men With Progressive Metastatic Castration-Resistant Prostate Cancer After Treatment With Abiraterone Acetate

Phase 1 Completed

Prostatic Neoplasms

NCT02333565 2023-05-25

CEVOREM

Phase 2 Completed

Meningioma

NCT01698918 2023-05-03

BOLERO-4

Phase 2 Completed

202 enrolled 19 charts

Breast Neoplasms

NCT02915783 2023-01-17

A Trial to Evaluate Efficacy and Safety of Lenvatinib in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Non Clear Cell Renal Cell Carcinoma (nccRCC) Who Have Not Received Any Chemotherapy for Advanced Disease

Phase 2 Completed

41 enrolled 11 charts

Neoplasm Metastasis

NCT03355794 2023-01-13

A Study of Ribociclib and Everolimus Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG)

Phase 1 Completed

Diffuse Intrinsic Pontine Glioma, Astrocytoma, Glioblastoma, Glioma

NCT02890069 2023-01-11

A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat

Phase 1 Completed

BreastGastrointestinalGenitourinaryThoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT01642186 2022-12-29

Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) With Leuprolide + Letrozole and (3) Everolimus + EDT in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLL-HCC)

Phase 2 Completed

28 enrolled 13 charts

Gastrointestinal

Fibrolamellar hepatocellular carcinoma

NCT00805129 2022-11-25

Everolimus (RAD001) in Metastatic Transitional Cell Carcinoma of the Urothelium

Phase 2 Completed

46 enrolled 11 charts

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT00830895 2022-11-09

RAD001 for Non-clear Cell Renal Cell Carcinoma (RCC)

Phase 2 Completed

Carcinoma, Renal Cell, Neoplasm Metastasis

NCT03163667 2022-09-15

ENTRATA

Phase 2 Completed

69 enrolled 12 charts

Carcinoma, Renal Cell

NCT00981162 2022-09-13

Sorafenib Tosylate and Everolimus in Treating Patients With Advanced Solid Tumors and Metastatic Pancreatic Cancer That Does Not Respond to Gemcitabine Hydrochloride

Phase 1 Completed

Gastrointestinal

Pancreatic Neoplasms

NCT02871791 2022-08-29

Palbociclib With Everolimus + Exemestane In BC

Phase 1/2 Completed

41 enrolled 12 charts

Human Epidermal Growth Factor 2 Negative Carcinoma of Breast

NCT02205515 2022-08-19

EBRT

Phase 1/2 Completed

Carcinoma, Neuroendocrine